GETI.B

210.8

-0.05%↓

CAMX

602

-0.41%↓

BIOAB

308.4

-3.08%↓

EKTA.B

57.05

+2.24%↑

VITR

141.2

+1.66%↑

GETI.B

210.8

-0.05%↓

CAMX

602

-0.41%↓

BIOAB

308.4

-3.08%↓

EKTA.B

57.05

+2.24%↑

VITR

141.2

+1.66%↑

GETI.B

210.8

-0.05%↓

CAMX

602

-0.41%↓

BIOAB

308.4

-3.08%↓

EKTA.B

57.05

+2.24%↑

VITR

141.2

+1.66%↑

GETI.B

210.8

-0.05%↓

CAMX

602

-0.41%↓

BIOAB

308.4

-3.08%↓

EKTA.B

57.05

+2.24%↑

VITR

141.2

+1.66%↑

GETI.B

210.8

-0.05%↓

CAMX

602

-0.41%↓

BIOAB

308.4

-3.08%↓

EKTA.B

57.05

+2.24%↑

VITR

141.2

+1.66%↑

Home・Aandelen Lijst・Vivesto AB

Vivesto AB

Gesloten

0.22

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.22

Max

0.22

Belangrijke statistieken
By Trading Economics
Inkomsten	2.3M -7.2M
EPS	-0.013
Werknemers	4

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-4.4M 74M
Vorige openingsprijs	0.22
Vorige sluitingsprijs	0.22

Vivesto AB Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 dec 2025, 20:41 UTC

Winsten

Belangrijke Marktbewegers

America's Car-Mart Rises on Better-Than-Expected 2Q Revenue, $300 Million Term Loan

4 dec 2025, 18:14 UTC

Acquisities, Fusies, Overnames

Big Yellow Says It Will Terminate Takeover Talks With Blackstone

4 dec 2025, 17:43 UTC

Belangrijke Marktbewegers

Acquisities, Fusies, Overnames

Brera Holdings Signs Non-Binding Term Sheet to Acquire RockawayX

4 dec 2025, 17:01 UTC

Winsten

TD Bank Pushes Up Dividend After Underlying Earnings, Revenue Beat Expectations -- Update

4 dec 2025, 23:45 UTC

Marktinformatie

Nikkei May Decline Amid Caution Over U.S. Labor Market, Japan Earnings -- Market Talk

4 dec 2025, 23:45 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

4 dec 2025, 21:54 UTC

Marktinformatie

Global Equities Roundup: Market Talk

4 dec 2025, 21:54 UTC

Marktinformatie

Warehouse's Strategy to Lift Margins Easier Said Then Done -- Market Talk

4 dec 2025, 21:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

4 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

4 dec 2025, 21:48 UTC

Marktinformatie

Scales Hits Mark With Earnings Guidance -- Market Talk

4 dec 2025, 21:37 UTC

Winsten

Aerospace Start-Up Beta Posts Its First Earnings Report. The Stock Rises. -- Barrons.com

4 dec 2025, 21:36 UTC

Winsten

These Stocks Moved the Most Today: Meta Platforms, Salesforce, Snowflake, UiPath, Micron, Dollar General, Kroger, and More -- Barrons.com

4 dec 2025, 20:15 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

4 dec 2025, 20:15 UTC

Marktinformatie

Think Tank Calls For Bank of Canada Rate Hold Next Week -- Market Talk

4 dec 2025, 20:04 UTC

Marktinformatie

Natural Gas Futures Extend Gains as U.S. Grows Cold -- Market Talk

4 dec 2025, 19:54 UTC

Marktinformatie

Oil Futures Bolstered by Lasting Ukraine War, U.S. Macro Outlook -- Market Talk

4 dec 2025, 19:44 UTC

Acquisities, Fusies, Overnames

EQB CEO: PC Financial Deal Adds Scale to Compete With Larger Canadian Banks

4 dec 2025, 19:44 UTC

Acquisities, Fusies, Overnames

EQB CEO: PC Financial Tie-Up Brings Scale to Reach More Customers

4 dec 2025, 19:44 UTC

Acquisities, Fusies, Overnames

Equitable Bank Deal for PC Financial Adds Heft to Compete With Canada's Big Banks -- Interview

4 dec 2025, 19:33 UTC

Marktinformatie

Gold Inches Higher as Traders Continue to Mull ADP Jobs Report -- Market Talk

4 dec 2025, 19:01 UTC

Acquisities, Fusies, Overnames

Paramount Raises Concerns About Netflix's Bid for Warner Bros. Discovery -- WSJ

4 dec 2025, 19:01 UTC

Acquisities, Fusies, Overnames

Paramount Wrote to Warner Bros. Discovery Again Wednesday -- WSJ

4 dec 2025, 19:01 UTC

Acquisities, Fusies, Overnames

Paramount Wrote Netflix Deal With Warner Bros. Would Likely 'Never Close,' Monday Letter Says -- WSJ

4 dec 2025, 19:01 UTC

Acquisities, Fusies, Overnames

Another Round of Bids for Warner Bros. Discovery Due Thursday, Sources Say -- WSJ

4 dec 2025, 18:58 UTC

Marktinformatie

U.S.-Venezuela Military Tension Expected to Lift Oil Prices -- Market Talk

4 dec 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

4 dec 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

4 dec 2025, 16:41 UTC

Marktinformatie

Gold Rises as Traders Await U.S. Inflation Data -- Market Talk

4 dec 2025, 16:33 UTC

Marktinformatie

Winsten

Salesforce Customers Are Gaining Confidence in Agentforce -- Market Talk

Peer Vergelijking

Prijswijziging

Vivesto AB Prognose

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.